635 related articles for article (PubMed ID: 36129048)
1. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
Verdugo E; Puerto I; Medina MÁ
Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
[TBL] [Abstract][Full Text] [Related]
4. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
[TBL] [Abstract][Full Text] [Related]
5. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
[TBL] [Abstract][Full Text] [Related]
6. Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions.
Hashemi M; Etemad S; Rezaei S; Ziaolhagh S; Rajabi R; Rahmanian P; Abdi S; Koohpar ZK; Rafiei R; Raei B; Ahmadi F; Salimimoghadam S; Aref AR; Zandieh MA; Entezari M; Taheriazam A; Hushmandi K
Biomed Pharmacother; 2023 Feb; 158():114204. PubMed ID: 36916430
[TBL] [Abstract][Full Text] [Related]
7. Voxtalisib and low intensity pulsed ultrasound combinatorial effect on glioblastoma multiforme cancer stem cells via PI3K/AKT/mTOR.
Tutak I; Ozdil B; Uysal A
Pathol Res Pract; 2022 Nov; 239():154145. PubMed ID: 36240647
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.
Sami A; Karsy M
Tumour Biol; 2013 Aug; 34(4):1991-2002. PubMed ID: 23625692
[TBL] [Abstract][Full Text] [Related]
9. Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).
Khabibov M; Garifullin A; Boumber Y; Khaddour K; Fernandez M; Khamitov F; Khalikova L; Kuznetsova N; Kit O; Kharin L
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35445737
[TBL] [Abstract][Full Text] [Related]
10. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137.
Wang L; Liu J; Zhong Z; Gong X; Liu W; Shi L; Li X
Brain Res; 2016 Sep; 1646():441-450. PubMed ID: 27328425
[TBL] [Abstract][Full Text] [Related]
11. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
[TBL] [Abstract][Full Text] [Related]
12. NQO1 drives glioblastoma cell aggressiveness through EMT induction via the PI3K/Akt/mTOR/Snail pathway.
Zheng L; Yang S; Xu R; Yang Y; Quan J; Lin Z; Quan C
Int J Oncol; 2023 Oct; 63(4):. PubMed ID: 37594082
[TBL] [Abstract][Full Text] [Related]
13. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.
Barzegar Behrooz A; Talaie Z; Jusheghani F; Łos MJ; Klonisch T; Ghavami S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163279
[TBL] [Abstract][Full Text] [Related]
14. AKT pathway genes define 5 prognostic subgroups in glioblastoma.
Joy A; Ramesh A; Smirnov I; Reiser M; Misra A; Shapiro WR; Mills GB; Kim S; Feuerstein BG
PLoS One; 2014; 9(7):e100827. PubMed ID: 24984002
[TBL] [Abstract][Full Text] [Related]
15. Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.
Kanwore K; Kanwore K; Adzika GK; Abiola AA; Guo X; Kambey PA; Xia Y; Gao D
Front Immunol; 2022; 13():831636. PubMed ID: 35392088
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia enhances the migration and invasion of human glioblastoma U87 cells through PI3K/Akt/mTOR/HIF-1α pathway.
Huang W; Ding X; Ye H; Wang J; Shao J; Huang T
Neuroreport; 2018 Dec; 29(18):1578-1585. PubMed ID: 30371540
[TBL] [Abstract][Full Text] [Related]
17. miR-548x and miR-4698 controlled cell proliferation by affecting the PI3K/AKT signaling pathway in Glioblastoma cell lines.
Kalhori MR; Arefian E; Fallah Atanaki F; Kavousi K; Soleimani M
Sci Rep; 2020 Jan; 10(1):1558. PubMed ID: 32005873
[TBL] [Abstract][Full Text] [Related]
18. HIF1α/HIF2α-Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR-PI3K/AKT signalling pathway with positive feedback under hypoxia.
Wang P; Zhao L; Gong S; Xiong S; Wang J; Zou D; Pan J; Deng Y; Yan Q; Wu N; Liao B
Cell Death Dis; 2021 Mar; 12(4):312. PubMed ID: 33762574
[TBL] [Abstract][Full Text] [Related]
19. mTOR-Dependent Cell Proliferation in the Brain.
Ryskalin L; Lazzeri G; Flaibani M; Biagioni F; Gambardella S; Frati A; Fornai F
Biomed Res Int; 2017; 2017():7082696. PubMed ID: 29259984
[TBL] [Abstract][Full Text] [Related]
20. PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells.
Udawant S; Litif C; Lopez A; Gunn B; Schuenzel E; Keniry M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
